MASLD, short for metabolic dysfunction-associated steatotic liver disease, is fat buildup in the liver tied to obesity, type 2 diabetes, and related conditions; MASH is its inflamed form. The 2026 ADA-EASD type 2 diabetes consensus report says MASLD affects more than 70% of people with type 2 diabetes.
GLP-1-based drugs cut liver fat sharply in trials. In a 98-person Phase 2a substudy published in Nature Medicine in 2024, retatrutide 12 mg reduced liver fat by 82.4% at 24 weeks, and 86% of people on that dose reached normal levels. On October 1, 2026, Novo reported a post hoc analysis in which liver fat fell below the 5% threshold in 23 of 26 Wegovy users in a small MRI subgroup.
See #mash, #retatrutide, and #wegovy.
An online survey of 760 U.S. hepatologists and gastroenterologists, endocrinologists, and primary care clinicians, conducted from November 2024 to January 2025 and published October 6, 2026 in Clinical and Translational Gastroenterology, found that 76.8% were very or extremely familiar with the GLP-1 receptor, compared with 53.9% for the GIP receptor and 30.1% for the glucagon receptor. Most still expected each type of agonist to help people with MASH: 90.3% for GLP-1, 75.9% for GIP, and 87.0% for glucagon receptor agonists. One author is a Boehringer Ingelheim employee; Boehringer is developing survodutide, a GLP-1 and glucagon dual agonist, for MASH.
Novo Nordisk reported on Thursday, October 1, 2026, at EASD in Milan, a post hoc, exploratory analysis pooling 1,919 adults from its STEP UP and STEP UP T2D trials who took Wegovy 7.2 mg, Wegovy 2.4 mg, or placebo. In a 55-person subgroup whose liver fat was measured by MRI, average liver fat fell from 8.8% at baseline to 3.1% at week 72, and 23 of the 26 participants who started above the 5% threshold for fatty liver ended below it. Liver fat was not a prespecified endpoint of either trial, and Novo pooled the two Wegovy doses for the MRI result.
Beyond TRIUMPH-1 and TRANSCEND-T2D-1, Lilly confirmed at ADA that seven additional Phase 3 retatrutide readouts span obesity, type 2 diabetes, osteoarthritis, obstructive sleep apnea, chronic low-back pain, metabolic dysfunction-associated steatotic liver disease (MASLD), and the cardiometabolic-outcomes program. The MASLD readout is on track for H1 2027, and TRIUMPH-OUTCOMES (cardiovascular events in a 10,000-patient population) anchors the late-2027 timeline.
In a 98-person substudy of the Phase 2 retatrutide obesity trial, published in Nature Medicine in 2024, liver fat fell 86.0% from baseline at 48 weeks on 12 mg versus 4.6% on placebo, and 93% of people on that dose with week-48 scans reached normal liver fat (below 5%); fewer than half of participants had week-48 MRIs. Lilly's Phase 3 SYNERGY-Outcomes trial (NCT07165028), which began in October 2025, is enrolling about 4,500 adults with MASLD at higher risk of serious liver outcomes to test retatrutide and tirzepatide against placebo, with time to the first major adverse liver outcome as its main endpoint.